Comparison of CellSearch and Circulating Tumor Cells (CTC)-Biopsy Systems in Detecting Peripheral Blood Circulating Tumor Cells in Patients with Gastric Cancer
- PMID: 33408319
- PMCID: PMC7802377
- DOI: 10.12659/MSM.926565
Comparison of CellSearch and Circulating Tumor Cells (CTC)-Biopsy Systems in Detecting Peripheral Blood Circulating Tumor Cells in Patients with Gastric Cancer
Abstract
BACKGROUND The purpose of this study was to compare circulating tumor cells (CTCs)/circulating tumor microemboli (CTM) detection rates of the CellSearch and CTC-Biopsy systems in patients with gastric cancer (GC). We also investigated potential correlations between clinicopathological characteristics and prognosis in patients with GC. MATERIAL AND METHODS This prospective study was conducted at the Shandong Institute of Cancer Prevention and Control in China. Fifty-nine patients with GC and 22 healthy volunteers were recruited and their peripheral blood samples were examined by the CTC-Biopsy system and CellSearch system for CTC. RESULTS The rate of detection of CTCs/CTM was significantly higher with the CTC-Biopsy system than with the CellSearch system (59.32% vs. 27.12%, P<0.001). The Kappa value was 0.179, indicating poor consistency. CTCs detected with the CellSearch system in patients with stage III/IV GC was significantly correlated with neutrophil count (P=0.020), neutrophil/lymphocyte ratio (N/L ratio) (P=0.009), CA19-9 (P=0.049), tumor size (P=0.026), and the extent of vascular invasion (P=0.007). CTCs detected with the CTC-Biopsy system correlated with tumor differentiation (P=0.010). CTM in patients with stage I/II GC and stage II/IV GC correlated with CEA (P=0.004) and tumor differentiation (P=0.030), respectively. A CTC count >3 detected with the CellSearch system, and not the CTC-Biopsy system, correlated with reduced progression-free survival and overall survival. CONCLUSIONS The CTC-Biopsy system was superior to the CellSearch system for detecting CTCs in GC patients. CTM were detected with the CTC-Biopsy system but not with the CellSearch system. CTCs detected with the CellSearch system correlated with various clinicopathological factors and long-term survival outcomes.
Conflict of interest statement
Among the authors listed in this paper, Li Sheng proposed the theory of circulating tumor cell detection and designed and verified the feasibility of the detection method. The CTC-Biopsy device was produced by Wuhan YZY Medical Technology Co, Ltd. YZY provided related equipment, testing supplies, and technical support. Li Sheng’s team carried out clinical trials and tests in Shandong Cancer Prevention and Control Institute. Li Sheng provided technical consulting services and academic promotion for the technical team of YZY. Li Sheng, Dawei Ning, Kai Cui, Min Liu, Yang Ou, Zhendan Wang, Benkui Zou, Yangyang Shen, Xinyang Lu, and Pang Li had no commercial interest in the CTC-Biopsy device. The terms of this arrangement have been reviewed and approved by the Shandong First Medical University and Shandong Academy of Medical Sciences in accordance with its policy on objectivity in research.
Figures




Similar articles
-
The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.Oncologist. 2019 Sep;24(9):e854-e863. doi: 10.1634/theoncologist.2018-0741. Epub 2019 Mar 7. Oncologist. 2019. PMID: 30846515 Free PMC article.
-
Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer.Breast Cancer Res Treat. 2022 Jun;193(2):437-444. doi: 10.1007/s10549-022-06585-5. Epub 2022 Apr 9. Breast Cancer Res Treat. 2022. PMID: 35397078 Free PMC article.
-
Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.PLoS One. 2013 Jun 28;8(6):e67466. doi: 10.1371/journal.pone.0067466. Print 2013. PLoS One. 2013. PMID: 23840710 Free PMC article. Clinical Trial.
-
Clinical significance of circulating tumor cells in gastric cancer patients.Oncotarget. 2017 Apr 11;8(15):25713-25720. doi: 10.18632/oncotarget.14879. Oncotarget. 2017. PMID: 28147337 Free PMC article. Review.
-
Challenges in circulating tumor cell detection by the CellSearch system.Mol Oncol. 2016 Mar;10(3):395-407. doi: 10.1016/j.molonc.2015.12.002. Epub 2015 Dec 25. Mol Oncol. 2016. PMID: 26795350 Free PMC article. Review.
Cited by
-
Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.Transl Cancer Res. 2022 Aug;11(8):2636-2646. doi: 10.21037/tcr-22-529. Transl Cancer Res. 2022. PMID: 36093536 Free PMC article.
-
Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer.J Oncol. 2022 Jan 11;2022:9635218. doi: 10.1155/2022/9635218. eCollection 2022. J Oncol. 2022. PMID: 35058982 Free PMC article.
-
Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis.Clin Exp Med. 2024 Mar 30;24(1):59. doi: 10.1007/s10238-024-01310-6. Clin Exp Med. 2024. PMID: 38554188 Free PMC article.
-
Clinical and Translational Applications of Serological and Histopathological Biomarkers in Metastatic Breast Cancer: A Comprehensive Review.Int J Mol Sci. 2023 May 7;24(9):8396. doi: 10.3390/ijms24098396. Int J Mol Sci. 2023. PMID: 37176102 Free PMC article. Review.
-
Role of circulating tumor DNA methylation in gastric cancer initiation and progression: A comprehensive review.World J Gastrointest Oncol. 2025 Aug 15;17(8):107412. doi: 10.4251/wjgo.v17.i8.107412. World J Gastrointest Oncol. 2025. PMID: 40837757 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous